Grace hunte and shuling liu from emory university rollins school of public health

Pediatric Infectious Disease Journal

Volumn 33, Issue SUPPL. 2, 2014, Pages

  Loo, Jennifer D ^a   Conklin, Laura ^a   Fleming Dutra, Katherine E ^a,b   Knoll, Maria Deloria ^c   Park, Daniel E ^c   Kirk, Jennifer ^d   Goldblatt, David ^e   O'Brien, Katherine L ^c   Whitney, Cynthia G ^a  

^a National Center for Immunizations and Respiratory Diseases   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d WESTAT   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Indirect effects; Nasopharyngeal carriage; Pneumococcal conjugate vaccine; Pneumococcal disease; Pneumonia

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

BACTERIAL COLONIZATION; DOSE RESPONSE; DRUG DOSE REGIMEN; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; PNEUMOCOCCAL INFECTION; PNEUMONIA; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; AGED; CHILD; HETEROZYGOTE; IMMUNIZATION; IMMUNOLOGY; INFANT; MICROBIOLOGY; MIDDLE AGED; NASOPHARYNX; OBSERVATIONAL STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARRIER STATE; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MIDDLE AGED; NASOPHARYNX; OBSERVATIONAL STUDY AS TOPIC; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84891436879     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000084     Document Type: Review

References (49)

1. P ilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
2. GAVI Alliance. Countries approved for support 2012. Geneva, Switzerland: GAVI Alliance; 2013. Available at: http://www.gavialliance.org/results/ countries-approved-for-support. Accessed April 15, 2013.
3. Conklin L, Loo JD, Kirk J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33 (Suppl 2):S109-S118.
4. Fleming-Dutra KE, Conklin L, Loo JD, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J. 2014;33 (Suppl 2):S152-S160.
5. Deloria Knoll M, Park D, Johnson TS, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J. 2014;33 (Suppl 2):S119-S129.
6. Loo JD, Conklin L, Fleming-Dutra KE, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J. 2014;33 (Suppl 2):S140-S151.
7. Ray GT, Pelton SI, Klugman KP, et al. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine. 2009;27:6483-6494.
8. Jennifer D, Loo JD, Conklin L, Deloria Knoll M, et al. Methods for a systematic review of pneumococcal conjugate vaccine dosing schedules. Pediatr Infect Dis J. 2014;33 (Suppl 2):S182-S187
9. O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007;196:1211-1220.
10. M ackenzie GA, Carapetis JR, Leach AJ, et al. Pneumococcal vaccination of Australian Aboriginal infants and pneumococcal carriage among adults and older children. 5th International Symposium on Pneumococci and Pneumococcal Diseases; April 2-6, 2006; Alice Springs, Australia. Abstract 122.
11. Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis. 2009;48:57-64.
12. Bettinger JA, Scheifele DW, Kellner JD, et al.; Canadian Immunization Monitoring Program, Active (IMPACT). The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine. 2010;28:2130-2136.
13. Cohen AL, Harrison LH, Farley MM, et al.; Active Bacterial Core Surveillance Team. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS. 2010;24:2253-2262.
14. Del Grosso M, Camilli R, D'Ambrosio F, et al. Serotype dynamic of invasive streptococcus pneumoniae before and after introduction of pneumococcal conjugate vaccine in Italy. ISPPD. 2010:132.
15. Flasche S, Robertson C, Diggle M, et al. Trends in serotypes among cases of invasive pneumococcal disease (IPD) in Scotland after introduction of PCV7. 7th International Symposium on Pneumococci and Pneumococcal Disease; March 14-18, 2010; Tel Aviv, Israel. Abstract 161.
16. Foster D. Invasive pneumococcal disease-initial impact of the conjugate vaccine in the Oxfordshire region of the UK. 6th International Symposium on Pneumococci and Pneumococcal Disease; June 8-12, 2008; Reykjavik, Iceland. Abstract 6.
17. Grau I, Ardanuy C, Liñares J, et al. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med. 2009;10:488-495.
18. Hanna JN, Humphreys JL, Murphy DM. Invasive pneumococcal disease in Indigenous people in north Queensland: an update, 2005-2007. Med J Aust. 2008;189:43-46.
19. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-256.
20. Jacobs MR, Good CE, Bajaksouzian S, et al. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis. 2008;47:1388-1395.
21. Kellner JD, Vanderkooi OG, MacDonald J, et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis. 2009;49:205-212.
22. L ambertsen L, Valentiner-Branth P, Harboe ZB, et al. Changes in the serotype distribution of invasive pneumococci after introduction of the PCV7 in Denmark, October 2007. 7th International Symposium on Pneumococci and Pneumococcal Disease; March 14-18, 2010; Tel Aviv, Israel. Abstract 166.
23. L ehmann D, Willis J, Moore HC, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis. 2010;50:1477-1486.
24. M iller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760-768.
25. M oore M, Farley M, Schaffner W, et al. Trends in invasive pneumococcal disease among adults, United States, 1998-2008. 7th International Symposium on Pneumococci and Pneumococcal Disease; March 14-18, 2010; Tel Aviv, Israel. Abstract 155.
26. Roche PW, Krause V, Cook H, et al.; Enhanced Invasive Pneumococcal Disease Surveillance Working Group; Pneumococcal Working Party of the Communicable Diseases Network Australia. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell Q Rep. 2008;32:18-30.
27. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010;16:816-823.
28. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-1792.
29. T yrrell GJ, Lovgren M, Chui N, et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre-and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine. 2009;27:3553-3560.
30. Vestrheim DF, Høiby EA, Bergsaker MR, et al. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine. 2010;28:2214-2221.
31. Weatherholtz R, Millar EV, Moulton LH, et al. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis. 2010;50:1238-1246.
32. Albrich WC, Madhi SA, Lafond KE, et al. Herd immunity after pneumococcal conjugate vaccination. Lancet. 2007;370:218-219; author reply 219.
33. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
34. Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J. 2010;29:607-612.
35. L in SH, Tan CK, Lai CC, et al. Declining incidence of nonbacteremic pneumococcal pneumonia [corrected] in hospitalized elderly patients at a tertiary care hospital after the introduction of pneumococcal vaccines in Taiwan, 2004 to 2008. J Am Geriatr Soc. 2010;58:195-196.
36. M etlay JP, Fishman NO, Joffe M, et al. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine. 2006;24:468-475.
37. N elson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26:4947-4954.
38. P atrzałek M, Albrecht P, Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis. 2010; 29:787-792.
39. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio. 2011;2:1-10.
40. Cheung YB, Zaman SM, Nsekpong ED, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J. 2009;28:990-995.
41. Flasche S, van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLos Med. 2011;8:1-9.
42. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis. 2006;193:1487-1494.
43. M illar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis. 2008;47:989-996.
44. Van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009;302:159-167.
45. Van Gils EJM, Veenhoven RH, Rodenburg GD, et al. Pneumococcal carriage in household contacts after reduced dose PCV-7 schedules in infants. 6th International Symposium on Pneumococci and Pneumococcal Disease; June 8-12, 2008; Reykjavik, Iceland. Abstract 384.
46. M oulton LH, O'Brien KL, Reid R, et al. Evaluation of the indirect effects of a pneumococcal vaccine in a community-randomized study. J Biopharm Stat. 2006;16:453-462.
47. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization -WHO position paper. Wkly Epidemiol Rec. 2012;14:129-144.
48. Russell FM, Carapetis JR, Satzke C, et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol. 2010;17:1970-1976.
49. Centers for Disease Control and Prevention. Progress in Introduction of Pneumococcal Conjugate Vaccine -Worldwide, 2000-2012. Morbid Mortal Wkly Rep. 2013;62:308-311.